Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Investig Clin Dent ; 9(4): e12347, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29893477

RESUMO

AIM: In the present study, we evaluated the clinical, radiographic, and histological comparisons of completely autologous titanium-prepared platelet rich fibrin (T-PRF) or allograft in sinus-lifting procedures. METHODS: Eighteen posterior maxilla requiring sinus-lifting procedures using the balloon-lifting technique for implant placement were selected. Ten sinuses were randomly assigned to T-PRF as the test group and eight to allografts as the control group. After 4 and 6 months in the test and control groups, respectively, computed tomography was done, and bone samples were received during implant surgery. Three months after the second surgery, implant stability was measured. RESULTS: Radiological results showed that the allograft group had better results (62% in volume, 53% in density, and 69% in height) than the T-PRF group. Histomorphometric results showed that newly-formed bone ratios were 17.28 ± 2.53 and 16.58 ± 1.05 in the allograft group and T-PRF groups, respectively. There was no significant difference between the test and control groups (P = .611) for implant stability values. CONCLUSIONS: The use of T-PRF alone in sinus-lifting operations has successful clinical and histomorphometric results. Bone formation in the T-PRF group was accelerated to 4 months compared to allografts according to the histological results.


Assuntos
Maxila/cirurgia , Fibrina Rica em Plaquetas , Levantamento do Assoalho do Seio Maxilar/métodos , Titânio/uso terapêutico , Adulto , Idoso , Transplante Ósseo/métodos , Feminino , Humanos , Masculino , Maxila/diagnóstico por imagem , Maxila/patologia , Pessoa de Meia-Idade , Fibrina Rica em Plaquetas/efeitos dos fármacos , Radiografia
2.
Br J Radiol ; 89(1058): 20140724, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26562095

RESUMO

OBJECTIVE: Contrast media (CM) are a major cause of nephropathy in high-risk patients. The aim of this study was to examine the effects of carnitine (CAR) in advanced nephrotoxicity due to CM administration in rats with glycerol-induced renal functional disorder. METHODS: 40 rats were divided randomly into five groups (n = 8): (1) healthy group; (2) glycerol only (GLY); (3) glycerol and CM (GLY + CM); (4) glycerol, CM and 200 mg kg(-1) carnitine (CAR200, Carnitene(®); Sigma-tau/Santa Farma, Istanbul, Turkey); and (5) glycerol, CM and 400 mg kg(-1) carnitine (CAR400). Kidney injury was induced with a single-dose, intramuscular injection of 10 ml kg(-1) body weight (b.w.) of GLY. CAR was administered intraperitoneally. CM (8 ml kg(-1) b.w. iohexol, Omnipaque™; Opakim Medical Products, Istanbul, Turkey) was infused via the tail vein to the rats in Groups 3-5. RESULTS: l-carnitine administration significantly decreased serum creatinine and blood urea nitrogen levels. Superoxide dismutase and glutathione activity increased significantly in the treatment groups compared with the nephrotoxic groups. CAR400 significantly reduced malondialdehyde levels to healthy levels. In the treatment groups, tumour necrosis factor (TNF)-α, transforming growth factor 1ß, interleukin 1ß and caspase-3 gene expression decreased compared with the nephrotoxic groups. TNF-α and nuclear factor kappa-beta (NF-κB) protein expression increased after CM and CAR administration reduced both TNF-α and NF-κB expressions. Histopathologically, hyaline and haemorrhagic casts and necrosis in proximal tubules increased in the nephrotoxicity groups and decreased in the CAR groups. CONCLUSION: The results reveal that l-carnitine protects the oxidant/antioxidant balance and decreases proinflammatory cytokines and apoptosis in CM-induced nephrotoxicity in rats with underlying pathology. ADVANCES IN KNOWLEDGE: Depending on the underlying kidney pathologies, the incidence of CM-induced nephropathy (CIN) increases. Therefore, this is the best model to represent clinically observed CIN.


Assuntos
Apoptose/efeitos dos fármacos , Carnitina/farmacologia , Meios de Contraste/toxicidade , Citocinas/sangue , Glicerol/toxicidade , Iohexol/toxicidade , Nefropatias/induzido quimicamente , Nefropatias/prevenção & controle , Estresse Oxidativo/efeitos dos fármacos , Animais , Nitrogênio da Ureia Sanguínea , Creatinina/sangue , Imuno-Histoquímica , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA